• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较罗匹尼罗对催乳素作用的激动-拮抗相互作用模型和池模型。

Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin.

机构信息

Department of Pharmaceutical Biosciences, Uppsala University, Sweden.

出版信息

Br J Clin Pharmacol. 2010 Dec;70(6):815-24. doi: 10.1111/j.1365-2125.2010.03758.x.

DOI:10.1111/j.1365-2125.2010.03758.x
PMID:21175437
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3014065/
Abstract

AIMS

The tolerance to the prolactin response following administration of antipsychotic drugs has been modelled as a depletion of a prolactin pool (pool model) and a model where the tolerance is explained by a feedback loop including the dopamine interaction of prolactin release (agonist-antagonist interaction model, (AAI model)). The AAI model was superior to the pool model when analyzing data from clinical trials of risperidone and paliperidone. Here we evaluated the two models using the remoxipride data, designed to challenge the short-term prolactin response, from which the original pool model was built.

METHODS

The remoxipride data were collected from a study where eight healthy male subjects received two remoxipride infusions on five occasions. The intervals between the first and second dose on each occasion were 2, 8, 12, 24 and 48 h, respectively. The pool and AAI models were fitted using NONMEM.

RESULTS

According to the objective function values the pool model with a circadian rhythm function fitted the data slightly better, while the AAI model was better in describing the circadian rhythm of prolactin. Visual predictive checks revealed that the models predicted the prolactin profiles equally well.

CONCLUSIONS

According to the analysis performed here, a previous analysis of several clinical studies and literature reports on prolactin concentrations, it appears that the dopamine feedback mechanism included in the AAI model is better than the storage depletion mechanism in the pool model to estimate the bio-rhythm of prolactin time-course and the tolerance development across different populations, drugs, treatment schedules and time.

摘要

目的

抗精神病药物给药后对催乳素反应的耐受性已被建模为催乳素池的耗竭(池模型)和一种通过包括催乳素释放的多巴胺相互作用的反馈环来解释耐受性的模型(激动剂-拮抗剂相互作用模型,(AAI 模型))。当分析利培酮和帕利哌酮临床试验的数据时,AAI 模型优于池模型。在这里,我们使用设计用于挑战短期催乳素反应的 remoxipride 数据(该数据来自原始池模型)来评估这两种模型。

方法

从一项研究中收集 remoxipride 数据,该研究中,八名健康男性受试者在五次不同时间接受两次 remoxipride 输注。每次的第一剂和第二剂之间的间隔分别为 2、8、12、24 和 48 小时。使用 NONMEM 拟合池模型和 AAI 模型。

结果

根据目标函数值,带有昼夜节律函数的池模型稍微更好地拟合数据,而 AAI 模型在描述催乳素的昼夜节律方面更好。视觉预测检查表明,这些模型同样很好地预测了催乳素曲线。

结论

根据这里进行的分析、对催乳素浓度的几项临床研究和文献报告的先前分析,似乎 AAI 模型中包含的多巴胺反馈机制比池模型中的存储耗竭机制更好,用于估计催乳素时间过程的生物节律和不同人群、药物、治疗方案和时间的耐受性发展。

相似文献

1
Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin.比较罗匹尼罗对催乳素作用的激动-拮抗相互作用模型和池模型。
Br J Clin Pharmacol. 2010 Dec;70(6):815-24. doi: 10.1111/j.1365-2125.2010.03758.x.
2
Modeling of prolactin response following dopamine D receptor antagonists in rats: can it be translated to clinical dosing?大鼠多巴胺 D 受体拮抗剂后催乳素反应的建模:能否转化为临床给药剂量?
Pharmacol Res Perspect. 2017 Dec;5(6). doi: 10.1002/prp2.364.
3
A comparison of two semi-mechanistic models for prolactin release and prediction of receptor occupancy following administration of dopamine D2 receptor antagonists in rats.大鼠体内多巴胺D2受体拮抗剂给药后催乳素释放及受体占有率预测的两种半机制模型比较
Eur J Pharmacol. 2016 Oct 15;789:202-214. doi: 10.1016/j.ejphar.2016.07.005. Epub 2016 Jul 6.
4
Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans.基于机制的催乳素生物学系统对急性多巴胺抑制挑战反应的 PK-PD 模型:对人类的定量外推。
J Pharmacokinet Pharmacodyn. 2012 Oct;39(5):463-77. doi: 10.1007/s10928-012-9262-4. Epub 2012 Jul 12.
5
Influence of the dosing interval on prolactin release after remoxipride.雷莫必利给药间隔对催乳素释放的影响。
Br J Clin Pharmacol. 1995 May;39(5):503-10. doi: 10.1111/j.1365-2125.1995.tb04487.x.
6
An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment.利培酮和帕利哌酮治疗后催乳素释放的激动剂 - 拮抗剂相互作用模型
Clin Pharmacol Ther. 2009 Apr;85(4):409-17. doi: 10.1038/clpt.2008.234. Epub 2008 Dec 24.
7
Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects.通过整合个体内和个体间因素的药代动力学-药效学模型研究瑞莫必利后的催乳素释放情况。
J Pharmacol Exp Ther. 1995 Aug;274(2):921-7.
8
Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist.非典型抗精神病药物瑞莫必利(一种多巴胺D2受体拮抗剂)的药理学
CNS Drug Rev. 2001 Fall;7(3):265-82. doi: 10.1111/j.1527-3458.2001.tb00199.x.
9
Pharmacokinetics and effects on prolactin of remoxipride in patients with tardive dyskinesia.迟发性运动障碍患者中瑞莫必利的药代动力学及对催乳素的影响。
Psychopharmacology (Berl). 1991;103(1):46-9. doi: 10.1007/BF02244072.
10
Remoxipride: pharmacokinetics and effect on plasma prolactin.瑞莫必利:药代动力学及对血浆催乳素的影响
Br J Clin Pharmacol. 1991 Sep;32(3):355-60. doi: 10.1111/j.1365-2125.1991.tb03911.x.

引用本文的文献

1
Quantification of the endogenous growth hormone and prolactin lowering effects of a somatostatin-dopamine chimera using population PK/PD modeling.采用群体 PK/PD 模型定量分析生长抑素-多巴胺嵌合体对内源性生长激素和催乳素的降低作用。
J Pharmacokinet Pharmacodyn. 2020 Jun;47(3):229-239. doi: 10.1007/s10928-020-09683-3. Epub 2020 Apr 4.
2
Modeling of prolactin response following dopamine D receptor antagonists in rats: can it be translated to clinical dosing?大鼠多巴胺 D 受体拮抗剂后催乳素反应的建模:能否转化为临床给药剂量?
Pharmacol Res Perspect. 2017 Dec;5(6). doi: 10.1002/prp2.364.
3
A two-step deconvolution-analysis-informed population pharmacodynamic modeling approach for drugs targeting pulsatile endogenous compounds.两步去卷积分析信息的群体药效动力学建模方法用于靶向内源性脉冲化合物的药物。
J Pharmacokinet Pharmacodyn. 2017 Aug;44(4):389-400. doi: 10.1007/s10928-017-9526-0. Epub 2017 May 11.
4
Revealing the Neuroendocrine Response After Remoxipride Treatment Using Multi-Biomarker Discovery and Quantifying It by PK/PD Modeling.使用多生物标志物发现揭示瑞莫必利治疗后的神经内分泌反应并通过药代动力学/药效学建模对其进行量化。
AAPS J. 2017 Jan;19(1):274-285. doi: 10.1208/s12248-016-0002-3. Epub 2016 Oct 26.
5
Predicting pharmacokinetic stability by multiple oral administration of atypical antipsychotics.通过多次口服非典型抗精神病药物预测药代动力学稳定性。
Innov Clin Neurosci. 2013 Mar;10(3):23-30.
6
Predictions of in vivo prolactin levels from in vitro K(i) values of D(2) receptor antagonists using an agonist-antagonist interaction model.使用激动剂-拮抗剂相互作用模型从 D(2)受体拮抗剂的体外 K(i) 值预测体内催乳素水平。
AAPS J. 2013 Apr;15(2):533-41. doi: 10.1208/s12248-012-9450-6. Epub 2013 Feb 8.
7
Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans.基于机制的催乳素生物学系统对急性多巴胺抑制挑战反应的 PK-PD 模型:对人类的定量外推。
J Pharmacokinet Pharmacodyn. 2012 Oct;39(5):463-77. doi: 10.1007/s10928-012-9262-4. Epub 2012 Jul 12.

本文引用的文献

1
An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment.利培酮和帕利哌酮治疗后催乳素释放的激动剂 - 拮抗剂相互作用模型
Clin Pharmacol Ther. 2009 Apr;85(4):409-17. doi: 10.1038/clpt.2008.234. Epub 2008 Dec 24.
2
Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder.利培酮和9-羟基利培酮在伴有双相I型障碍急性发作患者中的群体药代动力学。
J Pharmacokinet Pharmacodyn. 2007 Apr;34(2):183-206. doi: 10.1007/s10928-006-9040-2. Epub 2006 Nov 29.
3
Shift of monocyte function toward cellular immunity during sleep.睡眠期间单核细胞功能向细胞免疫的转变。
Arch Intern Med. 2006 Sep 18;166(16):1695-700. doi: 10.1001/archinte.166.16.1695.
4
PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.PsN工具包——一组使用NONMEM进行非线性混合效应建模的计算机密集型统计方法。
Comput Methods Programs Biomed. 2005 Sep;79(3):241-57. doi: 10.1016/j.cmpb.2005.04.005.
5
Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol.用[123I]碘苯甲酰胺和单光子发射计算机断层扫描(SPECT)测量的纹状体多巴胺2受体占有率可预测接受非典型抗精神病药物和氟哌啶醇治疗的患者发生锥体外系反应(EPS)的情况。
Psychopharmacology (Berl). 2002 Jun;162(1):42-9. doi: 10.1007/s00213-002-1082-6. Epub 2002 May 16.
6
Prolactin: structure, function, and regulation of secretion.催乳素:结构、功能及分泌调节
Physiol Rev. 2000 Oct;80(4):1523-631. doi: 10.1152/physrev.2000.80.4.1523.
7
Pharmacokinetic-pharmacodynamic modeling of tolerance to the prolactin-secreting effect of chlorprothixene after different modes of drug administration.不同给药方式后对氯丙硫蒽催乳素分泌作用耐受性的药代动力学-药效学建模。
J Pharmacol Exp Ther. 1999 Nov;291(2):547-54.
8
Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.Xpose——一种基于S-PLUS的用于NONMEM的群体药代动力学/药效学模型构建辅助工具。
Comput Methods Programs Biomed. 1999 Jan;58(1):51-64. doi: 10.1016/s0169-2607(98)00067-4.
9
Prolactin and antipsychotic medications: mechanism of action.
Schizophr Res. 1999 Mar 1;35 Suppl:S67-73. doi: 10.1016/s0920-9964(98)00158-3.
10
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.利培酮与新型及参比抗精神病药物的比较:体外和体内受体结合情况
Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73. doi: 10.1007/BF02245606.